Efficacy, safety, and patient acceptability of elvitegravir/cobicistat/emtricitabine/tenofovir in the treatment of HIV/AIDS

References

• LennoxJLLandovitzRJRibaudoHJEfficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trialAnn Intern Med2014161746147125285539
   PubMed Web of Science ®Google Scholar
• HazudaDJFelockPWitmerMInhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cellsScience2000287545364665010649997
   PubMed Web of Science ®Google Scholar
• StephanCBaldaufHMBarryJImpact of raltegravir on HIV-1 RNA and DNA forms following initiation of antiretroviral therapy in treatment-naive patientsJ Antimicrob Chemother201469102809281824962031
   PubMed Web of Science ®Google Scholar
• PommierYJohnsonAAMarchandCIntegrase inhibitors to treat HIV/AIDSNat Rev Drug Discov20054323624815729361
   PubMed Web of Science ®Google Scholar
• Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents (Downloaded from http://aidsinfo.nih.gov/guidelines on 4/15/2015). Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdfAccessed July 31, 2015
   Google Scholar
• ThompsonMAMugaveroMJAmicoKRGuidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panelAnn Intern Med20121561181783322393036
   PubMed Web of Science ®Google Scholar
• LeeFJAminJCarrAEfficacy of initial antiretroviral therapy for HIV-1 infection in adults: a systematic review and meta-analysis of 114 studies with up to 144 weeks’ follow-upPLoS One201495e9748224830290
   PubMed Web of Science ®Google Scholar
• Di BiagioAPrinaporiRGiannerelliDDuration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohortJ Antimicrob Chemother201368120020522915463
   PubMed Web of Science ®Google Scholar
• O’BrienMEClarksRABeschCLPatterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohortJ Acquir Immune Defic Syndr200334440741414615659
   PubMed Web of Science ®Google Scholar
• WilligJHAbromsSWestfallAOIncreased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapyAIDS200822151951196018784459
   PubMed Web of Science ®Google Scholar
• JayaweeraDDejesusENguyenKLVirologic suppression, treatment adherence, and improved quality of life on a once-daily efavirenz-based regimens in treatment naïve HIV-1 infected patients over 96 weeksHIV Clin Trials20091037538420133268
   PubMed Web of Science ®Google Scholar
• MaggioloFMigliorinoMMaseratiROnce-a day treatment for HIV infection. Final 48-week resultsPresented at: 8th Conference on Retroviruses and Opportunistic InfectionsFebruary 4–8 2001Chicago, IL Abstract 320
   Google Scholar
• NachegaJBParientiJJUthmanOALower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trialsClin Infect Dis2014581297130724457345
   PubMed Web of Science ®Google Scholar
• SaxPEDeJesusEMillsAGS-US-236-0102 study team. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment ofHIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeksLancet201237998352439244822748591
   PubMed Web of Science ®Google Scholar
• DeJesusERockstrohJKHenryKGS-236-0103 Study TeamCo-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trialLancet201237998352429243822748590
   PubMed Web of Science ®Google Scholar
• ZolopaASaxPEDeJesusEGS-US-236-0102 Study TeamA randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 resultsJ Acquir Immune Defic Syndr20136319610023392460
   PubMed Web of Science ®Google Scholar
• RockstrohJKDeJesusEHenryKGS-236-0103 Study TeamA randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 resultsJ Acquir Immune Defic Syndr201362548348623337366
   PubMed Web of Science ®Google Scholar
• WohlDACohenCGallantJEA randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 resultsJ Acquir Immune Defic Syndr2014653e118e12024256630
   PubMed Web of Science ®Google Scholar
• ClumeckNMolinaJMHenryKGS-236-0103 Study 96A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 resultsJ Acquir Immune Defic Syndr2014653e121e12424346640
   PubMed Web of Science ®Google Scholar
• PozniakAMarkowitzMMillsASwitching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trialLancet Infect Dis20141459059924908550
   PubMed Web of Science ®Google Scholar
• ArribasJRPialouxGGatheJSimplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trialLancet Infect Dis20141458158924908551
   PubMed Web of Science ®Google Scholar
• MillsACrofootGOrtizRSwitching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1- infected subjects: 48 weeks dataHIV Clin Trials201415515624710918
   PubMed Web of Science ®Google Scholar
• MathiasAAWestSHuiJKearneyBPDose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposureClin Pharmacol Ther2009851647018815591
   PubMed Web of Science ®Google Scholar
• GermanPLiuHCSzwarcbergJEffect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal functionJ Acquir Immune Defic Syndr2012611324022732469
   PubMed Web of Science ®Google Scholar
• StrayKMBamRABirkusGEvaluation of the effect of cobicistat on the in vitro renal transport and cytotoxicity potential of tenofovirAntimicrob Agents Chemother201357104982498923896476
   PubMed Web of Science ®Google Scholar
• PostFAWinstonJAndrade-VillanuevaJFStudy 118 TeamElvitegravir/cobicistat/emtricitabine/tenofovir df in hiv-infected patients with mild-to-moderate renal impairmentJ Acquir Immune Defic Syndr201568331031325469527
   PubMed Web of Science ®Google Scholar
• GermanPParmacokinetics of elvitegravir and cobicistat in subjects with severe renal impairmentPoster presented at: 13th International Workshop on Clinical Pharmacology of HIV TherapyApril 16–18 2012Barcelona, Spain Poster number 38
   Google Scholar
• RockstrohJKLennoxJLDejesusELong-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1 infected patients: 156-week results from STARTMRKClin Infect Dis20115380781621921224
   PubMed Web of Science ®Google Scholar
• EronJJYoungBCooperDASWITCHMRK 1 and 2 investigators. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trialsLancet2010375971239640720074791
   PubMed Web of Science ®Google Scholar
• MartinezEd’AlbuquerquePMLlibreJthe SPIRAL Study GroupChanges of cardiovascular biomarkers in HIV-infected patients switching from ritonavir boosted protease inhibitor to raltegravirAIDS2012262315232623018438
   PubMed Web of Science ®Google Scholar
• BiancoCMeiniGRossettiBSwitch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNAJ Int AIDS Soc2014174 Suppl 31979125397535
   PubMed Web of Science ®Google Scholar
• HilemanCOKinleyBScharen-GuivelVDifferential reduction in monocyte activation and vascular inflammation with integrase inhibitor-based initial antiretroviral therapyJ Infect Dis2015212334535425583168
   PubMed Web of Science ®Google Scholar
• GandhiMGandhiRTSingle-pill combination regimens for treatment of HIV-1 infectionN Engl J Med2014371324825925014689
   PubMed Web of Science ®Google Scholar
• ParientiJJBangsbergDRVerdonRGardnerEMBetter adherence with once-daily antiretroviral regimens: a meta-analysisClin Infect Dis200948448448819140758
   PubMed Web of Science ®Google Scholar
• StellbrinkHJAntinoriAPozniakASwitch to stribild versus continuation of NVP or RPV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-NNRTI subgroup analysisJ Int AIDS Soc2014174 Suppl 31979325397537
   PubMed Web of Science ®Google Scholar
• ArribasJRizzardiniGArastehKSimplification to Stribild vs continuation of RTV-boosted DRV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-PI subgroup analysisJ Int AIDS Soc2014174 Suppl 31980525397549
   PubMed Web of Science ®Google Scholar
• Stribild® registration in the developing world Available from: https://www.gilead.com/~/media/Files/pdfs/other/Stribild%20Registration%20102414.pdfAccessed July 31, 2015
   Google Scholar